arrow
S

Stephen Lockhart

pfizer
H指数:31
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B Clostridioides difficile Vaccine in Adults 50 Years and Older

随机化III期比较:针对50岁及以上成人使用的去毒化的产气荚膜梭菌A/B毒素疫苗的2剂和3剂免疫程序

2026-05-190
OA
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old

奥密克戎BA.1适配的BNT162b2新冠疫苗第四剂在18-55岁成年人中的安全性与免疫原性

2026-02-010
PRE
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection

三叶草 (艰难梭菌疫苗功效试验) 研究: 一项3期随机试验,研究解毒毒素A/B疫苗在50岁及以上艰难梭菌感染风险增加的成年人中的功效和安全性

2024-08-243
OAAI
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age

BNT162b2新型冠状病毒肺炎疫苗在5岁以下儿童中的应用评价

2023-02-1645
OAAI
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years

55岁以上成人的二价Omicron BA.1适应BNT162b2助推器

2023-01-1973
OAAI
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
2022-01-06432
OAAI
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
2021-10-21276
OAAI
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

BNT162b2新型冠状病毒肺炎疫苗在青少年中的安全性、免疫原性和有效性

2021-07-15656
OAAI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

BNT162b2 mRNA Covid-19疫苗的安全性和有效性

2020-12-311.1W
OAAI
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
2020-12-171.9K
OAAI
Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21α
2016-08-1766
OAAI
Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever
2016-05-2339
OAAI
LIVE ATTENUATED ORAL VACCINE, AGE AND ANTI-VI ANTIBODY STATUS AT BASELINE SIGNIFICANTLY AFFECT ATTACK RATE IN A HUMAN SALMONELLA TYPHI CHALLENGE MODEL
2015-12-010
OAAI
An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate Solution
2014-02-10114
OAAI